- Case report
- Open Access
Huge parathyroid carcinoma: Clinical considerations and literature review
© Chiofalo et al; licensee BioMed Central Ltd. 2005
Received: 07 February 2005
Accepted: 23 June 2005
Published: 23 June 2005
Parathyroid carcinoma is a rare malignancy, with an incidence of 0.5 to 4% of all cases of primary hyperparathyroidism. Surgery is the only curative treatment.
We report the case of a 66-year-old man referred for a large suspicious substernal goitre associated with severe hypercalcemia due to hyperparathyroidism. After normalization of serum calcium levels, patient underwent surgery. The voluminous cervicomediastinal firm mass could not be removed through the cervical incision; therefore a cervicothoracic approach was employed. Histopathology revealed a giant parathyroid cancer of 450 grams. A review of the literature was also undertaken to summarize the current treatment approaches for this rare malignancy.
Parathyroid cancer is usually not recognized either preoperatively or intra-operatively. En bloc resection of the tumour with the adjacent tissue is the treatment of choice and it is very important to avoid the rupture of the capsule during operation. Neither tumour size, nor the lymph node status appears to play a role in prognosis. The management of parathyroid carcinoma is a challenge even for experienced surgeons.
Parathyroid Carcinoma (PC) is a rare malignancy with an incidence of 0.5 to 4% in all patients surgically treated for primary hyperparathyroidism [1, 2]. Generally the tumour is solitary, although recently a double parathyroid carcinoma has been reported . This tumour has a high probability to recur locally and to spread to regional nodes and distant sites. It is difficult to diagnose parathyroid cancer preoperatively. Often local invasion at operation and subsequent histological examination reveal malignancy and differentiation from a benign parathyroid adenoma can be difficult even after histological examination. However, the presence of some signs such as profound hypercalcemia, markedly elevated levels of parathormone and a clinically palpable cervical mass can raise suspicion preoperatively of a malignant lesion [1, 2, 4, 5].
We report the case of a patient admitted to our department for a large substernal goitre suspected to be a thyroid cancer, associated with severe hyperparathyroidism.
Preoperative laboratory values
Postoperative laboratory values
2.30 mg/dl (0.60 – 1.30)
4.00 mg/dl (0.60 – 1.30)
825 U/L (50 – 140)
500 U/L (50 – 140)
14.2 mg/dl (8.4 – 10.5)
6.3 mg/dl (8.4 – 10.5)
3.1 mg/dl (2.5 – 5.0)
2.4 mg/dl (2.5 – 5.0)
1828 pg/ml (10.0 – 65.0)
20.9 pg/ml (10.0 – 65.0)
The patient was vigorously hydrated and bisphosphonates were given preoperatively to control hypercalcemia. Eight days later the serum calcium level decreased to 10.4 mg/dl. With the above clinical findings, the patient underwent surgical neck exploration.
At surgery a voluminous cervicomediastinal firm mass was found that could not be removed via the superior thoracic strait; therefore a complete sternotomy was performed. The surgical findings revealed an ovoid, grayish-yellow, hard mass, measuring 12 × 9 × 8 cm, adherent to the base of the left lobe of the thyroid, extending to the anterior upper mediastinum; the recurrent laryngeal nerve was laterally displaced but not invaded. Therefore en bloc resection of the mass along with the total thyroid gland and the connective tissue apparently involved in the tumour was performed. All the lymphoid tissue from the ipsilateral tracheoesophageal groove to the upper mediastinum was removed
At follow-up, three, six, nine and 12 months after surgery, the patient was disease-free with normal levels of PTH and calcaemia and improvement of the bone disease symptoms. Whole body positron emission tomography (PET) performed one year after surgery was negative.
Parathyroid carcinoma is a rare disease and the preoperative diagnosis is often difficult because clinical manifestations are similar, although more often severe than in patients with parathyroid adenomas. Parathyroid carcinomas are generally larger and firmer than parathyroid adenomas. The clinical manifestations of hyperparathyroidism are usually more severe, and serum levels of calcium, PTH and alkaline phosphatase are significantly higher than in patients with adenoma. Patients with parathyroid carcinoma have a high incidence of renal dysfunction, osteoporosis and gastrointestinal symptoms [1, 2, 4].
Preoperative and intraoperative suspicion is important in planning the effective surgical treatment: the complete resection of the tumour at the first neck exploration is reported to provide the best chance of cure. The optimal surgical treatment is en bloc resection with ipsilateral thyroid lobectomy and removal of any enlarged or abnormal lymph nodes. Most of the authors emphasize the importance of an aggressive initial approach in reducing local and distant recurrences [4, 6–12]. Particular attention must be given to avoid rupture of the tumour during surgery, because of the very high risk of local seeding and persistent or recurrent disease [4, 13]; in these cases, local surgical excision is useful for palliation but is rarely curative [14, 15].
The management of the recurrent laryngeal nerve is more controversial but it should be resected only when it is not functioning preoperatively or is invaded by tumour [1, 4, 15, 16]. The clinical behaviour of parathyroid carcinoma is variable, some patients are cured, others have an indolent course; recurrent or persistent disease occurs in about 50% of cases; usually the tumour recurs within 3 years after initial operation, although much longer intervals have been described [4, 6, 17, 18]. Surgery is the treatment of choice even for recurrent and persistent disease when the site of tumour can be localized: lung metastases are the most frequent type of recurrences after local recurrences; Hundley et al, have recently reported a case of resection of multiple PC lung metastases 20 years after the initial neck surgery, with a significant improvement of clinical and metabolic complications after removal of metastatic parathyroid cancer from both lungs .
Recently some authors have reported a role for adjuvant radiation therapy. Neck and mediastinum adjuvant irradiation has been reported to be useful in reducing the risk of loco-regional disease progression and in improving survival [16, 22–24]. Other reports suggest a positive effect of radiotherapy for palliating symptoms of hypercalcaemia in inoperable patients [23–25].
In our case, although the laboratory data revealed marked hyperparathyroidism and the patient had all the signs and symptoms of severe hyperparathyroidism, none of the preoperative localizing studies raised suspicion of the presence of a parathyroid carcinoma. The slow growth of the mass and the preoperative FNAB suggested a large substernal goitre with malignant transformation; only the postoperative histological exam revealed a diagnosis of parathyroid cancer.
This is an interesting case because of the large size of the parathyroid cancer with regional nodal metastases without any evidence of distant metastases or local recurrence one year after initial surgery. In the literature parathyroid cancers ranges from 1.5 to 6 cm in diameter and from 1.5 to 27 grams in weight [18, 26]. A case of giant paratyroid carcinoma of 1200 grams with nodal involvement, presenting as a substernal goitre has been reported; it was "en bloc" resected and the patient was alive and disease free after 4 years . The tumour size does not appear to play a role in the prognosis; the larger tumours in fact don't seem more likely to recur than the smaller ones. In the experience recently reported by Clayman neither local invasiveness seems to correlate with likelihood of recurrence [16, 28]. Our case too confirms that many biologic factors involved in the clinical course of parathyroid cancer remain unclear. Most of the parathyroid cancers are diagnosed after surgery and often only after reoperation for local or distant recurrence; many patients have a good clinical course despite the type of the initial operation; others have recurrent or persistent hypercalcemia and severe metabolic complications that can be difficult to control and often result in death . The outcome of the patients with parathyroid carcinoma depends on the biologic features and on the management of the recurrent disease more than on initial therapy. In the future an understanding of molecular pathogenesis of this rare malignancy could provide a means for early diagnosis and new treatment strategies. [16, 29].
Based on current knowledge, clinicians should consider parathyroid carcinoma in differential diagnosis when patients present with severe hyperparathyroidism and a palpable cervical mass. When there is an intraoperative suspicion of malignancy, a complete surgical resection should be undertaken with special attention to avoid the rupture of the capsule of the tumour. We believe this approach offers the best chance for a successful outcome.
We thank Mrs Jane Bryce for her kind collaboration in the review of the manuscript Patient consent was obtained for publication of this case report
- Levin KE, Galante M, Clark OH: Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcaemia. Surgery. 1987, 101: 649-660.PubMedGoogle Scholar
- Shortell CK, Andrus CH, Phillips CE, Schwartz SI: Carcinoma of the parathyroid gland: A 30-year experience. Surgery. 1991, 110: 704-708.PubMedGoogle Scholar
- Kamemaya K, Takami H: Double parathyroid carcinoma. Endocrine Journal. 2003, 50: 477-479. 10.1507/endocrj.50.477.View ArticleGoogle Scholar
- Shane E:Parathyroid carcinoma. J Clin Endocrinol Metab. 2001, 86: 485-493. 10.1210/jc.86.2.485.View ArticlePubMedGoogle Scholar
- Castillo L, Poissonnet G, Haddad A, Guevara N, Santini J, Demard F: Parathyroid carcinoma: diagnosis and treatment. Rev Laryngol Otol Rhinol (Bord). 2000, 121: 169-73.Google Scholar
- Kebebew E: Parathyroid Carcinoma. Curr Treat Options Oncol. 2001, 2: 347-354.View ArticlePubMedGoogle Scholar
- Hoelting T, Weber T, Werner J, Herfarth C: Surgical treatment of parathyroid carcinoma. Oncol Rep. 2001, 8: 931-934.PubMedGoogle Scholar
- Sheehan JJ, Hill AD, Walsh MF, Crotty TB, McDermott EW, O'Higgings NJ: Parathyroid carcinoma: diagnosis and management. Eur J Surg Oncol. 2001, 27: 321-324. 10.1053/ejso.2001.1043.View ArticlePubMedGoogle Scholar
- Snell SB, Gaar EE, Stevens SP, Flynn MB: Parathyroid cancer, a continued diagnostic and therapeutic dilemma: report of four cases and review of literature. Am Surg. 2003, 69: 711-716.PubMedGoogle Scholar
- Dotzenrath C, Goretzki PE, Serbia M, Cupisti K, Feldkamp J, Roher HD: Parathyroid carcinoma: problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol. 2001, 27: 383-389. 10.1053/ejso.2001.1122.View ArticlePubMedGoogle Scholar
- Pelizzo MR, Piotto A, Bergamasco A, Rubello D, Casara D: Il carcinoma delle paratiroidi. Strategie terapeutiche derivate da 20 anni di esperienza. Minerva Endocrinol. 2001, 26: 23-29.PubMedGoogle Scholar
- Favia G, Lumachi F, Polistina F, D'amico DF: Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg. 1998, 22: 1225-1230. 10.1007/s002689900549.View ArticlePubMedGoogle Scholar
- Sandelin K, Thompson NW, Bondeson L: Metastaticparathyroid carcinoma dilemmas in management. Surgery. 1991, 110: 978-988.PubMedGoogle Scholar
- Holmes EC, Morton DL, Ketcham AS: Parathyroid carcinoma: a collective review. Ann Surg. 1969, 169: 631-640.PubMed CentralView ArticlePubMedGoogle Scholar
- Vetto JT, Brennan MF, Woodruf J, Burt M: Parathyroid carcinoma: Diagnosis and clinical history. Surgery. 1993, 114: 882-892.PubMedGoogle Scholar
- Clayman GL, Gonzales HE, El Naggar A, Vassilopoulou R: Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer. 2004, 100: 900-905. 10.1002/cncr.20089.View ArticlePubMedGoogle Scholar
- Kebebew E, Arici C, Duh QY, Clark OH: Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001, 136: 878-885. 10.1001/archsurg.136.8.878.View ArticlePubMedGoogle Scholar
- De Lellis RA: Parathyroid Carcinoma. Atlas of tumour pathology, Tumours of the Parathyroid Gland. 3rd series. Armed force Institute of Pathology. 1993, Washington DC, 6: 53-62.Google Scholar
- Hundley JC, Albertson DA, Bradley RF, Levine EA: Resection of pulmonary metastasis from parathyroid carcinoma. Am Surg. 2003, 69: 779-783.PubMedGoogle Scholar
- Dubost C, Jehanno C, Lavergna A, Le charpentier Y: Successful resection of intrathoracic metastases from two patients with parathyroid carcinoma. World J Surg. 1984, 8: 547-551. 10.1007/BF01654934.View ArticlePubMedGoogle Scholar
- Obara T, Okamoto T, Ito Y, Yamashita T, Kawano M, Nishi T, Tani M, Sato K, Demura H, Fujimoto Y: Surgical and medical management of patients with pulmonary metastasis from parathyroid carcinoma. Surgery. 1993, 114: 1040-1049.PubMedGoogle Scholar
- Munson ND, Foot RL, Northcutt RC, Tiegs RD, Fitzpatrick LA, Grant CS, van Heerden JA, Thompson GB, Lloyd RV: Parathyroid carcinoma: is there a role for adjuvant radiation therapy?. Cancer. 2003, 98: 2378-2384. 10.1002/cncr.11819.View ArticlePubMedGoogle Scholar
- August DA, Flynn SD, Jones MA, Bagwell CB, Kinder BK: Parathyroid carcinoma: the relationship of nuclear DNA content to clinical outcome. Surgery. 1993, 113: 290-296.PubMedGoogle Scholar
- Chow E, Tsang RW, Brierley JD, Filice S: Parathyroid carcinoma-the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1998, 41: 569-572. 10.1016/S0360-3016(98)00098-4.View ArticlePubMedGoogle Scholar
- Rasmuson T, Kristoffersson A, Boquist L: Positive effect of radiotherapy ad surgery on hormonally active pulmonary metastases of primary parathyroid carcinoma. Eur J Endocrinol. 2000, 143: 749-754. 10.1530/eje.0.1430749.View ArticlePubMedGoogle Scholar
- Shanz A, Castelman B: Parathyroid carcinoma: a study of 70 cases. Cancer. 1973, 31: 600-605.View ArticleGoogle Scholar
- Avramides A, Papamargaritis K, Antoniadis A, Gakis D: Large parathyroid functioning carcinoma (1,200 g) presenting as a substernal goiter. J Endocrinol Invest. 1992, 15: 39-42.View ArticlePubMedGoogle Scholar
- Hundahl SA, Fleming ID, Fremgen AM, Menck HR: Two hundred and eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995. a national cancer data base report. Cancer. 1999, 86: 538-544. 10.1002/(SICI)1097-0142(19990801)86:3<538::AID-CNCR25>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Shattuk TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A: Somatic and Germ-line mutation of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003, 349: 1722-1729. 10.1056/NEJMoa031237.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.